Funds and ETFs Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:34 2024-05-27 EDT 5-day change 1st Jan Change
92.03 CHF +0.32% Intraday chart for Novartis AG -1.44% +8.44%

ETFs positioned on Novartis AG

Name Weight AuM 1st Jan change Investor Rating
10.40% 121 M€ -.--% -
5.57% 17 M€ +7.56% -
4.12% 88 M€ +10.37% -
3.79% 2 M€ -25.75%
2.74% 838 M€ +10.11%
2.70% 4 M€ -.--% -
2.55% 6 M€ -.--%
2.53% 6 M€ -.--% -
2.00% 3 M€ +9.95% -
1.50% 32 M€ +7.50% -
1.44% 29 M€ +8.37% -
1.43% 2 M€ +9.19% -
1.43% 2 M€ -.--% -
1.41% 242 M€ +9.26%
1.20% 48 M€ +10.05%
1.15% 10 M€ -3.35% -
1.00% 7 M€ +5.87% -
0.98% 7 M€ +0.11% -
0.97% 17 M€ 0.00%
0.74% 1,083 M€ +4.23%
0.71% 5 M€ -.--% -
0.53% 284 M€ -.--%
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
100.7 USD
Average target price
108.2 USD
Spread / Average Target
+7.44%
Consensus
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. Funds and ETFs Novartis AG